

The clinical significance of silent mutations with respect to ciprofloxacin resistance in MRSA

Chih-Cheng Lai¹
Chi-Chung Chen^{2,3}
Ying-Chen Lu³
Yin-Ching Chuang^{2,4}
Hung-Jen Tang^{5,6}

¹Department of Intensive Care Medicine, Chi Mei Medical Center, Liouying, Tainan, Taiwan; ²Department of Medical Research, Chi Mei Medical Center, Tainan, Taiwan; ³Department of Food Science, National Chiayi University, Chiayi, Taiwan; ⁴Department of Internal Medicine, Chi Mei Medical Center, Liouying, Tainan, Taiwan; ⁵Department of Health and Nutrition, Chia-Nan University of Pharmacy and Science, Tainan, Taiwan; ⁶Department of Medicine, Chi Mei Medical Center, Tainan, Taiwan

Background: The aim of this study was to investigate the genotypic differences between different sequence type MRSA isolates, especially focusing on silent *rpoB474* mutations and the relationship between such mutations and ciprofloxacin resistance.

Methods: Seventy-nine MRSA isolates were obtained for antibiotic susceptibility tests and molecular study.

Results: Among these isolates, we found that the MIC₅₀, MIC₉₀, and minimum inhibitory concentration (MIC) range of ciprofloxacin were much higher for the isolates without the *rpoB474* mutation than for isolates with the *rpoB474* mutation. A total of 87.5% of the isolates with the *rpoB474* mutation were susceptible to ciprofloxacin, but none of the isolates without the *rpoB474* mutation were susceptible to ciprofloxacin. For 27 MRSA isolates without *rpoB474* silent mutation but with *gyrA86/126* silent mutation, all of them belonged to SCCmec III, and had high ciprofloxacin MIC levels. For another 44 MRSA isolates with *rpoB474* silent mutation but without *gyrA86/126* silent mutation, all of them showed low ciprofloxacin MIC levels, all of them belonged to either SCCmec IV or V. Furthermore, MRSA ciprofloxacin resistance was found to be associated with the mutations *gyrA S84L/parC S80F* or *gyrA S84L*, and *S85P/parC S80Y*.

Conclusion: Most occurrences of this *rpoB474* silent mutation were found in community acquired-MRSA (CA-MRSA) isolates with susceptibility to most antibiotics, especially for ciprofloxacin and vice versa. Thus, this mutation may help to differentiate the different microbiologic characteristics of MRSA clinical isolates.

Keywords: MRSA, silent mutation, *rpoB474*, ciprofloxacin, resistance

Introduction

The emergence of methicillin-resistant *Staphylococcus aureus* (MRSA) infections has become a substantial treatment challenge in hospital-associated settings and in community settings around the world.^{1–3} In addition to methicillin, MRSA can develop antimicrobial resistance against several different antibiotic classes, including β -lactams, quinolones, trimethoprim-sulfamethoxazole, erythromycin, clindamycin, linezolid, and daptomycin, through various resistance gene mutations, including *blaZ*, *mecA*, *parC*, *gyrA*, *gyrB*, *sulA*, *dfxB*, *erm*, *cfr*, and *mprF*.^{4–8} There is no exception for the *rpoB* gene, which encodes the β -subunit of the bacterial RNA polymerase. The mutation of this gene following rifampicin therapy can often lead to the emergence of rifampicin resistance.⁹ Therefore, rifampicin resistance can be detected by sequencing the *rpoB* gene. Hellmark et al demonstrated that *rpoB* sequencing could be an accurate method of species identification in *staphylococci*,⁹ and Marty et al reported that the highly discriminatory *rpoB* species-specific PCR-RFLP analysis allows for fast and simple molecular identification

Correspondence: Hung-Jen Tang, Department of Medicine, Chi Mei Medical Center, No.901, Zhonghua Rd., Yongkang Dist., Tainan City 710, Taiwan
Tel +886 6 2812811 ext 52606
Fax +886 6 2832057
Email 8409d1@gmail.com

of *Staphylococcus* and other bacteria.¹⁰ This finding suggests that the *rpoB* gene may have the potential role as one of the core gene candidates for phylogenetic analyses and bacterial identification. Our recent study on the *rpoB* gene found that a point mutation in codon 474 (AAC → AAT) located in cluster I region¹¹ was present in 60% of our clinical MRSA isolates, and this mutation was not associated with any induction of rifampicin resistance and was even associated with lower antibiotic resistance rates, especially for ciprofloxacin.¹² Therefore, this study was conducted to investigate the genotypic differences among different sequence type MRSA isolates, especially focusing on silent mutations and the relationship between such mutations and ciprofloxacin resistance.

Materials and methods

Clinical isolates

Seventy-nine MRSA isolates were obtained from the Tigecycline In-vitro Surveillance in Taiwan (TIST) study at 22 hospitals from 2006 to 2010.¹³ *Staphylococci* were identified by colony morphology, Gram stain, and coagulase test results. MRSA was further confirmed by the tube coagulase test and growth on 6 µg/mL oxacillin salt agar screening plates. The *mecA* gene was confirmed using a PCR method. Isolates were stored at −70°C in Protect Bacterial Preservers (Technical Service Consultants Limited, Heywood, UK) until use.

Antibiotic susceptibility test

Antibiotics tested included chloramphenicol, erythromycin, gentamicin, minocycline, oxacillin, rifampin, and vancomycin (Sigma-Aldrich Co., St Louis, MO, USA), fosfomycin (Ercros, Barcelona, Spain), linezolid and tigecycline (Pfizer, Inc., New York, NY, USA), fusidic acid (Leo Pharma, Ballerup, Denmark), teicoplanin (Sanofi-Aventis, Bridgewater, NJ, USA), ciprofloxacin (Bayer AG, Leverkusen, Germany), daptomycin (Merck & Co., Inc., Kenilworth, NJ, USA). Interpretation criteria for the susceptibility test and the minimum inhibitory concentration (MIC) determined by the agar dilution tests were based on the recommendations of the Clinical and Laboratory Standards Institute (CLSI) or the British Society for Antimicrobial Chemotherapy.^{14–16} For the fosfomycin susceptibility test, glucose-6-phosphate (25 mg/L) was added to the agar plate. The daptomycin susceptibility test was performed in Mueller–Hinton broth adjusted to 50 mg/L of calcium per standard methodology. Mueller–Hinton agar (Thermo Fisher Scientific, Waltham, MA, USA) was employed for *S. aureus* MIC determination. Inocula were prepared by suspending growth from overnight cultures in saline to a turbidity of a 0.5 McFarland standard. Inoculated plates were then incubated in ambient air at 37°C

for 24 h. *S. aureus* ATCC 29213 was included as the control strain in each of the MIC measurements.

Determination of the *mecA*, PVL, *rpoB*, *gyrA* and *parC* gene mutation

PCR for the *mecA* gene was performed according to the protocol described by Vannuffel et al.¹⁷ *S. aureus* ATCC BAA-1707, USA400 was used as the positive control. A 433-bp nucleotide fragment located in the *lukS*-PV and *lukF*-PV operons was amplified by PCR using the primers and conditions described by Lina et al.¹⁸ The primer sequence was *lukPV*-forward (ATC ATT AGG TAA AAT GTC TGG ACA TGA TCC A) and reverse (GCA TCA AAT GTA TTG GAT AGC AAA AGC). The PCR method was used to amplify these genes including *rpoB*, *gyrA*, and *parC* with gene mutations using primers and previously described cycling conditions.^{19, 20} The following primers were used: (a) *rpoB*-forward (CCG TCG TTT ACG TTC TGT AGG) and reverse (AAA GCC GAA TTC ATT TAC ACG); (b) *gyrA*-forward (AAT GAA CAA GGT ATG ACA CC) and reverse (TAC GCG CTT CAG TAT AAC GC); (c) *parC*-forward (ACT TGA AGA TGT TTT AGG TGA T) and reverse (TTA GGA AAT CTT GAT GGC AA). Template DNA for PCR was prepared using InstaGene™ Matrix as recommended by the manufacturer (Bio-Rad Laboratories Inc., Hercules, CA, USA). After amplification, PCR products were purified from excess primers and nucleotides using a QIAquick PCR Purification Kit (QIAGEN, Valencia, CA, USA) and sequenced with the same primers by the dideoxy chain termination method in an ABI PRISM 3730 sequence analyzer (Thermo Fisher Scientific, Waltham, MA, USA).

Molecular typing methods

All isolates were analyzed by SCC*mec* typing, MLST typing, and pulsed-field gel electrophoresis (PFGE). The SCC*mec* types were determined by the multiplex PCR strategy developed by Kondo et al.²¹ The MLST was carried out as previously described.²² The sequences of the PCR products were compared with the existing sequences available on the MLST website (<http://saureus.mlst.net>) for *S. aureus*.²³ DNA extraction and SmaI restriction were performed as previously described. The PFGE patterns were visually examined and interpreted according to the criteria developed by Tenover et al.²⁴ The similarities of PFGE profiles of each strain were compared using a Dice coefficient at 1.0% of tolerance and 0.8% of optimization.

Results

The PFGE patterns of all MRSA isolates were shown in Figure 1. Two isolates did not yield an interpretable result with PFGE analysis because of technical problems associated




Figure 1 PFGE and molecular patterns of MRSA isolates.

Abbreviations: PFGE, pulsed-field gel electrophoresis; MRSA, methicillin-resistant *Staphylococcus aureus*; opt, optimization; tol, tolerance; PVL, Pantone–Valentine leucocidin; ST, sequence type; TIST, Tigecycline In-vitro Surveillance in Taiwan.

Table 1 The MIC values of MRSA isolates according the presence of the *rpoB474* silent mutation

Antibiotics	No <i>rpoB474</i> silent mutation (n=31)				<i>rpoB474</i> silent mutation (n=48)				MIC interpretive criteria		
	MIC ₅₀ , mg/L	MIC ₉₀ , mg/L	MIC range, mg/L	Susceptibility, %	MIC ₅₀ , mg/L	MIC ₉₀ , mg/L	MIC range, mg/L	Susceptibility, %	S	I	R
OXA	> 128	> 128	4→ 128	0.0	16	128	<1→ 128	14.6	≤2		≥ 4
ERY	> 128	> 128	0.5→ 128	3.2	> 128	> 128	0.5→ 128	6.3	≤0.5	1–4	≥ 8
GEN	> 128	> 128	<1→ 128	9.7	<1	> 128	<1→ 128	50.0	≤4	8	≥ 16
CM	16	16	8–64	0.0	64	128	8–128	0.0	≤0.5	1–2	≥ 4
VA	2	2	1–2	100	1	2	1–2	100	≤2	4–8	≥ 16
TGC	0.5	1	0.25–1	83.9	0.5	0.5	0.25–1	95.8	≤0.5 ^a		
MNO	8	8	0.125–8	45.2	0.25	0.5	0.125–8	95.8	≤4	8	≥ 16
TEC	2	2	0.5–2	100	1	1	0.5–2	100	≤8	16	≥ 32
FA	0.5	8	0.5–8	71.0	0.25	0.5	0.25–8	97.9	≤1 ^b		
LNZ	4	4	2–4	100	4	8	2–8	89.6	≤4		≥ 8
CIP	> 64	> 64	16→ 64	0.0	0.5	2	0.25→ 64	87.5	≤1	2	≥ 4
RIF	0.016	2	0.016→ 32	80.6	0.016	2	0.016→ 32	89.6	≤1	2	≥ 4
FOS	16	32	1→ 1024	90.3	4	8	1→ 1024	95.8	≤32 ^b		
DAP	0.5	1	0.125–1	100	0.25	0.5	0.25–1	100	≤1		

Notes: ^aMIC interpretive criteria were assessed according to the FDA guidelines. ^bMIC interpretive criteria were assessed according to the BSAC guidelines.

Abbreviations: MRSA, methicillin-resistant *Staphylococcus aureus*; MIC, minimum inhibitory concentration; OXA, oxacillin; ERY, erythromycin; GEN, gentamicin; CM, clindamycin; VA, vancomycin; TGC, tigecycline; MNO, minocycline; TEC, teicoplanin; FA, fusidic acid; LNZ, linezolid; CIP, ciprofloxacin; RIF, rifampicin; FOS, fosfomycin; DAP, daptomycin; S, susceptible; I, intermediate; R, resistant.

with degradation of the genomic DNA. This may lead to only very faint bands, degraded bands, or no banding patterns. Only 26 (32.9%) MRSA isolates were Pantone–Valentine leukocidin (PVL) positive. The most common sequence type (ST) was ST59 (n=41, 51.8%), followed by ST239 (n=26, 32.9%), ST5 (n=4, 5.0%), ST8 (n=2, 2.5%), ST45 (n=2, 2.5%), ST573 (n=2, 2.5%), ST388 (n=1, 1.3%), and ST900 (n=1, 1.3%).

Table 1 shows the MICs and the susceptibility of 48 and 31 MRSA isolates with and without the *rpoB474* silent mutation, respectively. All isolates were susceptible to vancomycin, teicoplanin, and daptomycin. For oxacillin, erythromycin, gentamicin, tigecycline, minocycline, fusidic acid, rifampicin, and fosfomycin, the susceptibility rates of 48 *rpoB474* silent mutation isolates were higher than those of the 31 unmutated *rpoB474* isolates. In contrast, the susceptibility rate against linezolid of the non-*rpoB474* silent mutation isolates was 100% and higher than *rpoB474* silent mutation isolates susceptibility rate of 89.6%. For ciprofloxacin, we found a significant difference regarding MICs and the susceptibility rate between isolates with and without the *rpoB474* silent mutation. The MIC₅₀, MIC₉₀, and MIC range was much higher for the isolates without the *rpoB474* silent mutation than with the *rpoB474* silent mutation. A total of 87.5% of the isolates with the *rpoB474* silent mutation were susceptible to ciprofloxacin, but none of the isolates without the *rpoB474* silent mutation were susceptible to ciprofloxacin.

Table 2 shows the association between the ciprofloxacin MIC and the gene mutations. For 27 MRSA isolates without *rpo474* silent mutation but with *gyrA86/126* silent mutation (Group A), all of them belonged to SCCmec III and had the double mutations in the *gyrA* and *parC* genes, such as *gyrA* S84L/*parC* S80F or *gyrA* S84L. Moreover, all of Group A MRSA isolates showed high ciprofloxacin MIC levels. For four MRSA isolates with *rpo474* silent mutation but without *gyrA86/126* silent mutation (Group B), all of these presented with high ciprofloxacin MIC level, but only three of them had double mutations in the *gyrA* and *parC* genes. For four MRSA isolates without *rpo474* and *gyrA86/126* silent mutation (Group C), all of them had double mutations in the *gyrA* and *parC* genes, and high ciprofloxacin MIC levels. For 44 MRSA isolates with *rpo474* silent mutation but without *gyrA86/126* silent mutation (Group D), all of them showed low ciprofloxacin MIC level, but none of them had double mutations in the *gyrA* and *parC* genes. Among group D, MRSA isolates belonged to either SCCmec IV or V.

Table 3 summarizes the distribution of SCCmec types and silent mutations of *rpoB474* and *gyrA86/126* among all clinical isolates. For 27 SCCmec type III MRSA isolates, none had the *rpoB474* silent mutation, but all had the *gyrA86/126* silent mutation. In contrast, for most of the SCCmec type IV and V isolates, the *rpoB474* silent mutation rate was 95.5% and 96.2%, respectively. None of the isolates had the *gyrA86/126* silent mutation.

Table 2 The ciprofloxacin MIC values of MRSA isolates with respect to the *rpoB474* and *gyrA86/126* gene mutations

<i>rpoB 474/gyrA 86, 126 sm</i>	Isolates	Ciprofloxacin MIC	<i>gyrA</i>	<i>parC</i>	SCCmec
Group A					
-/+	TIST4	> 64	S84L	S80F	III
-/+	TIST5	> 64	S84L	S80F	III
-/+	TIST12	> 64	S84L	S80F	III
-/+	TIST17	> 64	S84L	S80F	III
-/+	TIST18	> 64	S84L	S80F	III
-/+	TIST34	> 64	S84L	S80F	III
-/+	TIST35	> 64	S84L	S80F	III
-/+	TIST36	> 64	S84L/ G108D	S80F	III
-/+	TIST49	> 64	S84L	S80F	III
-/+	TIST53	> 64	S84L	S80F	III
-/+	TIST54	> 64	S84L	S80F	III
-/+	TIST56	> 64	S84L	S80F	III
-/+	TIST57	32	S84L	S80F	III
-/+	TIST59	> 64	S84L	S80F	III
-/+	TIST62	> 64	S84L/ S85P	S80F	III
-/+	TIST66	> 64	S84L	S80F	III
-/+	TIST68	64	S84L/ E88L	S80F/ E84K	III
-/+	TIST69	64	S84L	S80F	III
-/+	TIST73	> 64	S84L/ S85P	S80F	III
-/+	TIST74	> 64	S84L/ S85P	S80F	III
-/+	TIST83	> 64	S84L/ S85P	S80F	III
-/+	TIST85	> 64	S84L	S80F	III
-/+	TIST89	> 64	S84L	S80F	III
-/+	TIST92	64	S84L/ S85P	S80F	III
-/+	TIST94	> 64	S84L	S80F/S81P	III
-/+	TIST98	> 64	S84L	S80F	III
-/+	TIST100	> 64	S84L	S80F	III
Group B					
+/-	TIST19	32	x	x	V
+/-	TIST44	> 64	S84L	S80Y	II
+/-	TIST51	> 64	S84L	S80Y	II
+/-	TIST95	16	S84L (110sm)	S80F (77sm)	IV
Group C					
-/-	TIST26	> 64	S84L/ S85P	R61L/ S80Y/ S81P	II
-/-	TIST42	> 64	S84L	S80Y	IV
-/-	TIST47	16	S84L (110sm)	S80F (77sm)	V
-/-	TIST71	> 64	S84L	S80Y	II
Group D					
+/-	TIST2	0.25	x	x	IV
+/-	TIST3	0.5	x	x	IV

(Continued)

Table 2 (Continued)

<i>rpoB 474/gyrA 86, 126 sm</i>	Isolates	Ciprofloxacin MIC	<i>gyrA</i>	<i>parC</i>	SCCmec
+/-	TIST7	0.25	x	x	IV
+/-	TIST8	0.25	x	x	V
+/-	TIST10	0.25	x	x	IV
+/-	TIST11	0.5	x	x	V
+/-	TIST13	0.25	x	x	V
+/-	TIST14	0.25	x	x	V
+/-	TIST15	0.5	x	x	V
+/-	TIST21	0.25	x	x	V
+/-	TIST22	0.25	x	x	V
+/-	TIST23	0.25	x	x	IV
+/-	TIST28	0.25	x	x	V
+/-	TIST29	0.25	x	x	V
+/-	TIST30	0.25	x	x	IV
+/-	TIST31	0.25	x	x	V
+/-	TIST37	1	x	x	IV
+/-	TIST40	1	x	x (77/81/ 113sm)	V
+/-	TIST41	0.5	x	x	V
+/-	TIST43	0.5	x	x	V
+/-	TIST45	1	x	x	V
+/-	TIST46	0.5	x	x	V
+/-	TIST48	0.5	x	x	IV
+/-	TIST50	1	x	x	IV
+/-	TIST52	1	x	x	IV
+/-	TIST55	1	x	x	IV
+/-	TIST58	0.5	x	x	V
+/-	TIST61	1	x	x	V
+/-	TIST63	1	x	x	IV
+/-	TIST65	0.25	x	x	IV
+/-	TIST70	0.25	x	x	V
+/-	TIST72	2	x	E84K	V
+/-	TIST75	1	x	x	IV
+/-	TIST76	1	x	S80F/ S123F	IV
+/-	TIST77	0.25	x	x	V
+/-	TIST79	0.5	x	x	IV
+/-	TIST80	0.5	x	x	V
+/-	TIST81	0.25	x	x	V
+/-	TIST82	1	x	x (77/ 81/113sm)	V
+/-	TIST86	0.25	x	x	V
+/-	TIST87	1	x	S80F/ S123F	IV
+/-	TIST88	0.25	x	x	IV
+/-	TIST93	2	x	S80F	IV
+/-	TIST97	0.25	x	x	IV

Notes: Group A: *rpoB474* wild type/*gyrA86* and *126* mutation with high ciprofloxacin MIC. Group B: *rpoB474* mutation/*gyrA86* and *126* wild type with high ciprofloxacin MIC. Group C: *rpoB474* wild type/*gyrA86* and *126* wild type with high ciprofloxacin MIC. Group D: *rpoB474* mutation/*gyrA86* and *126* wild type with low ciprofloxacin MIC.

Abbreviations: MRSA, methicillin-resistant *Staphylococcus aureus*; MIC, minimum inhibitory concentration; TIST, Tigecycline In-vitro Surveillance in Taiwan.

Table 3 MRSA isolate SCCmec patterns

SCCmec	Numbers	No. (%) of MRSA isolates with <i>rpoB</i> 474 mutations	No. (%) of MRSA isolates with <i>gyrA</i> 86/126 mutation
II	4	2 (50)	0 (0)
III	27	0 (0)	27 (100)
IV	22	21 (95.5)	0 (0)
V	26	25 (96.2)	0 (0)

Notes: *rpoB*474: 474aac-aat silent mutation. *gyrA*86/126: 86att-attc/126gcg-gca silent mutation.

Abbreviation: MRSA, methicillin-resistant *Staphylococcus aureus*.

Discussion

This study had several interesting findings regarding the association between *rpoB*474 silent mutations and the different SCCmec and ST type MRSA isolates. Nearly all of the 48 MRSA isolates (Groups B and D) carried SCCmec type IV and V had the *rpoB*474 silent mutation. In contrast, none of them had the *gyrA*86/126 silent mutation and most of them do not have double mutations of *gyrA*/*parC* gene. Furthermore, these isolates exhibit high susceptibility to ciprofloxacin, and other antibiotics. All of these characteristics are consistent with microbiological features of community-acquired-MRSA (CA-MRSA).^{25,26} Additionally, most of the CA-MRSA isolates in this study were found to be ST59, which is the major type of CA-MRSA in Taiwan.^{27,28} In contrast, for the group of 31 MRSA isolates without the *rpoB*474 silent mutation (Groups A and C), all of them had the double mutations in the *gyrA* and *parC* genes, and showed high ciprofloxacin MIC levels. Among them, SCCmec type III compromised most of the MRSA isolates (n=27, 87.1%). These findings indicate that MRSA without the *rpoB*474 silent mutation is associated with higher resistance to ciprofloxacin, and most of these isolates should be classified as hospital-acquired MRSA (HA-MRSA) carrying SCCmec type III. In summary, we found the different presentations between MRSA isolates with and without *rpoB*474 silent mutation and this mutation may help differentiate the different microbiologic characteristic of MRSA clinical isolates.

In this study, MRSA ciprofloxacin resistance was found to be associated with the mutations of *gyrA* S84L/*parC* S80F or *gyrA* S84L, S85P/*parC* S80Y. This is consistent with previous findings that double mutants in the *parC* and *gyrA* genes may cause high-level resistance to ciprofloxacin with an MIC value ≥ 64 mg/dL.²⁹ Meanwhile, we also found a reciprocal relationship of *rpoB*474, *gyrA*86/126 silent mutation and *gyrA*/*parC* mutation that had never been reported before. Previous study suggested that *rpoB* mutation could be a “regulatory” mutation to decrease vancomycin

susceptibility in heterogeneous vancomycin-intermediate *S. aureus* (hVISA) and VISA phenotype acquisition.^{30,31} In addition, the role of *rpoB* mutation in the ciprofloxacin resistance has been demonstrated in the study of *Escherichia coli* with ciprofloxacin-selected *rpoB* mutations.³² Pietsch et al found that the mutations in RNA polymerase can be served as novel contributors to the evolution of resistance to ciprofloxacin and also significantly increase the expression of *mdtK*, encoding a multidrug efflux transporter.³² However, *rpoB*474 and *gyrA*86/126 mutations in this study are silent mutations. In contrast to true mutation, they just have nucleotide change but do not result in new amino acid substitute. Therefore, whether the finding is incidental or significant among MRSA isolates remains unclear. Further study is warranted to investigate possible mechanisms.

Conclusion

We found the phenomenon about the relationship between *rpoB*474, *gyrA*86/126 silent mutation and *gyrA*/*parC* mutation with ciprofloxacin MIC and antibiotic resistance. Most occurrences of this *rpoB*474 silent mutation were found in CA-MRSA isolates with susceptibility to most antibiotics, especially for ciprofloxacin. In contrast, most of MRSA isolates without this mutation are HA-MRSA with high resistance to ciprofloxacin.

Acknowledgment

This study was supported by a research grant (nos. CMFHT10501, CMNCKU10509) from the Chi-Mei Medical Center Research Foundation, and MOST 105-2314-B-384-007-MY3 from Ministry of Science and Technology.

Disclosure

The authors report no conflicts of interest in this work.

References

1. Boucher HW, Corey GR. Epidemiology of methicillin-resistant *Staphylococcus aureus*. *Clin Infect Dis*. 2008;46 (Suppl 5):S344–S349.
2. Chen CJ, Huang YC. Community-acquired methicillin-resistant *Staphylococcus aureus* in Taiwan. *J Microbiol Immunol Infect*. 2005;38(6): 376–382.
3. Lee CM, Lai CC, Chiang HT, et al. Presence of multidrug-resistant organisms in the residents and environments of long-term care facilities in Taiwan. *J Microbiol Immunol Infect*. 2017;50(2):133–144.
4. Mishra NN, Yang SJ, Sawa A, Rubio A, Nast CC, Yeaman MR, Bayer AS. Analysis of cell membrane characteristics of in vitro-selected daptomycin-resistant strains of methicillin-resistant *Staphylococcus aureus*. *Antimicrob Agents Chemother*. 2009;53(6):2312–2318.
5. Lowy FD. Antimicrobial resistance: the example of *Staphylococcus aureus*. *J Clin Invest*. 2003;111(9):1265–1273.
6. Stryjewski ME, Corey GR. Methicillin-resistant *Staphylococcus aureus*: an evolving pathogen. *Clin Infect Dis*. 2014;58 (Suppl 1):S10–S19.

7. Malachowa N, DeLeo FR. Mobile genetic elements of *Staphylococcus aureus*. *Cell Mol Life Sci*. 2010;67(18):3057–3071.
8. Gu B, Kelesidis T, Tsioudas S, Hindler J, Humphries RM. The emerging problem of linezolid-resistant *Staphylococcus*. *J Antimicrob Chemother*. 2013;68(1):4–11.
9. Hellmark B, Soderquist B, Unemo M. Simultaneous species identification and detection of rifampicin resistance in *staphylococci* by sequencing of the *rpoB* gene. *Eur J Clin Microbiol Infect Dis*. 2009;28(2):183–190.
10. Marty E, Buchs J, Eugster-Meier E, Lacroix C, Meile L. Identification of *staphylococci* and dominant lactic acid bacteria in spontaneously fermented Swiss meat products using PCR-RFLP. *Food Microbiol*. 2012;29(2):157–166.
11. Aubry-Damon H, Galimand M, Gerbaud G, Courvalin P. *rpoB* mutation conferring rifampin resistance in *Streptococcus pyogenes*. *Antimicrob Agents Chemother*. 2002;46(5):1571–1573.
12. Tang HJ, Lai CC, Hsueh PR, et al. RNA polymerase B subunit gene mutations in biofilm-embedded methicillin-resistant *Staphylococcus aureus* following rifampin treatment. *J Microbiol Immunol Infect*. 2016;49(3):394–401.
13. Hsueh PR. Tigecycline in-vitro surveillance in Taiwan (TIST). *Int J Antimicrob Agents*. 2008;32 (Suppl 3):S173.
14. Andrews JM. Determination of minimum inhibitory concentrations. *J Antimicrob Chemother*. 2001;48 (Suppl 1):5–16.
15. CLSI. Methods for dilution antimicrobial susceptibility tests for bacteria that grow aerobically; approved standard. 9th ed. M7–A9. Wayne, PA: Clinical & Laboratory Standards Institute; 2006.
16. CLSI. Performance standards for antimicrobial susceptibility testing; Sixteenth Informational Supplement M100–S24. Wayne, PA: Clinical & Laboratory Standards Institute; 2014.
17. Vannuffel P, Gigi J, Ezzedine H, Vandercam B, Delmee M, Wauters G, Gala JL. Specific detection of methicillin-resistant *Staphylococcus* species by multiplex PCR. *J Clin Microbiol*. 1995;33(11):2864–2867.
18. Lina G, Piémont Y, Godail-Gamot F, et al. Involvement of Pantone–Valentine leukocidin-producing *Staphylococcus aureus* in primary skin infections and pneumonia. *Clin Infect Dis*. 1999;29(5):1128–1132.
19. Kwak YG, Truong-Bolduc QC, Bin Kim H, Song KH, Kim ES, Hooper DC. Association of *norB* overexpression and fluoroquinolone resistance in clinical isolates of *Staphylococcus aureus* from Korea. *J Antimicrob Chemother*. 2013;68(12):2766–2772.
20. Wichelhaus TA, Schäfer V, Brade V, Böddinghaus B. Molecular characterization of *rpoB* mutations conferring cross-resistance to rifamycins on methicillin-resistant *Staphylococcus aureus*. *Antimicrob Agents Chemother*. 1999;43(11):2813–2816.
21. Kondo Y, Ito T, Ma XX, Watanabe S, Kreiswirth BN, Etienne J, Hiramatsu K. Combination of multiplex PCRs for staphylococcal cassette chromosome *mec* type assignment: Rapid identification system for *mec*, *ccr*, and major differences in junkyard regions. *Antimicrob Agents Chemother*. 2007;51(1):264–274.
22. Enright MC, Day NP, Davies CE, Peacock SJ, Spratt BG. Multilocus sequence typing for characterization of methicillin-resistant and methicillin-susceptible clones of *Staphylococcus aureus*. *J Clin Microbiol*. 2000;38(3):1008–1005.
23. Ip M, Lyon DJ, Chio F, Enright MC, Cheng AF. Characterization of isolates of methicillin-resistant *Staphylococcus aureus* from Hong Kong by phage typing, pulsed-field gel electrophoresis, and fluorescent amplified-fragment length polymorphism analysis. *J Clin Microbiol*. 2003;41(11):4980–4985.
24. Tenover FC, Arbeit RD, Goering RV, Mickelsen PA, Murray BE, Persing DH, Swaminathan B. Interpreting chromosomal DNA restriction patterns produced by pulsed-field gel electrophoresis: Criteria for bacterial strain typing. *J Clin Microbiol*. 1995;33(9):2233–2239.
25. Jung SI, Shin DH, Park KH, Shin JH. Antimicrobial susceptibility and clonal relatedness between community- and hospital-acquired methicillin-resistant *Staphylococcus aureus* from blood cultures. *J Microbiol*. 2006;44(3):336–343.
26. Gostev V, Kruglov A, Kalinogorskaya O, et al. Molecular epidemiology and antibiotic resistance of methicillin-resistant *Staphylococcus aureus* circulating in the Russian Federation. *Infect Genet Evol*. 2017;53:189–194.
27. Feng Y, Chen HL, Chen CJ, Chen CL, Chiu CH. Genome comparisons of two Taiwanese community-associated methicillin-resistant *Staphylococcus aureus* ST59 clones support the multi-origin theory of CA-MRSA. *Infect Genet Evol*. 2017;54:60–65.
28. Huang YC, Chen CJ. Community-associated methicillin-resistant *Staphylococcus aureus* in children in Taiwan, 2000s. *Int J Antimicrob Agents*. 2011;38(1):2–8.
29. Ferrero L, Cameron B, Crouzet J. Analysis of *gyrA* and *glaA* mutations in stepwise-selected ciprofloxacin-resistant mutants of *Staphylococcus aureus*. *Antimicrob Agents Chemother*. 1995;39(7):1554–1558.
30. Watanabe Y, Cui L, Katayama Y, Kozue K, Hiramatsu K. Impact of *rpoB* mutations on reduced vancomycin susceptibility in *Staphylococcus aureus*. *J Clin Microbiol*. 2011;49(7):2680–2684.
31. Miller N1, Rudoy RC. Vancomycin intermediate-resistant *Staphylococcus aureus* (VISA). *Orthop Nurs*. 2000;19(6):45–48; quiz 49–51.
32. Pietsch F, Bergman JM, Brandis G, Marcusson LL, Zorzet A, Huseby DL, Hughes D. Ciprofloxacin selects for RNA polymerase mutations with pleiotropic antibiotic resistance effects. *J Antimicrob Chemother*. 2017;72(1):75–84.

Infection and Drug Resistance

Publish your work in this journal

Infection and Drug Resistance is an international, peer-reviewed open-access journal that focuses on the optimal treatment of infection (bacterial, fungal and viral) and the development and institution of preventive strategies to minimize the development and spread of resistance. The journal is specifically concerned with the epidemiology of antibiotic

Submit your manuscript here: <https://www.dovepress.com/infection-and-drug-resistance-journal>

resistance and the mechanisms of resistance development and diffusion in both hospitals and the community. The manuscript management system is completely online and includes a very quick and fair peer-review system, which is all easy to use. Visit <http://www.dovepress.com/testimonials.php> to read real quotes from published authors.

Dovepress